Abstract：Objective: To investigate the effect and mechanism of SP2509 combined with cisplatin on apoptosis and autophagy of osteosarcoma cells. Methods: The expression of LSD1 in osteosarcoma cells MG-63,HuO9,U-2OS and human osteoblast hFoB1.19 were detected by qRT-PCR.The IC50 values of SP2509 and cisplatin were detected by CCK8 method.MG-63 cells were divided into control group,SP2509 group (20μmoL/L),cisplatin group (10μmoL/L),SP2509(20μmoL/L) combined with cisplatin group (10μmoL/L),the level of apoptosis was detected by flow cytometry,and the expressions of LDSS1,LC3-Ⅱ,p62,caspase 3 and Bcl-2 were detected by Western blot. Results: The expression of LSD1 in osteosarcoma cells MG-63,HuO9 and U-2OS was significantly higher than that in hFoB1.19,and the expression of LSD1 was the highest in MG-63.The IG50 values of SP2509 and cisplatin were 40 and 20μmoL/L.Compared with the control group,the apoptosis level of MG-63 cells in SP2509 group and cisplatin group increased significantly (P<0.05),the expression of caspase 3 increased significantly (P<0.05),the expression of Bcl-2 decreased significantly (P<0.05),the expression of LC3-Ⅱ increased significantly (P<0.05),the expression of p62 decreased significantly (P<0.05),and the expression of LSD1 decreased significantly (P<0.05).The level of apoptosis in SP2509 combined with cisplatin group was significantly higher than that in SP2509 group and cisplatin group (P<0.05),the expression of Caspase 3 and LC3-Ⅱ was significantly higher than that in SP2509 group and cisplatin group (P<0.05),and the expression of Bcl-2,P62 and LSD1 was significantly lower than that in SP2509 group and cisplatin group (P<0.05). Conclusion: SP2509 combined with cisplatin can induce apoptosis and autophagy of osteosarcoma cells by regulating the expression of LSD1.
[1] Fernandes I,Melo-Alvim C,Lopes-Bras R,et al.Osteosarcoma pathogenesis leads the way to new target treatments[J].Int Mol Sci,2021,22(2):813-831. [2] Yahiro K,Matsumoto Y.Immunotherapy for osteosarcoma[J].Hum Vaccin Immunother,2021,17(5):1294-1295. [3] Smrke A,Anderson PM,Gulia A,et al.Future directions in the treatment of osteosarcoma[J].Cells,2021,10(1):172-182. [4] Fang Y,Yang C,Yu Z,et al.Natural products as LSD1 inhibitors for cancer therapy[J].Acta Pharm Sin B,2020,11(3):621-631. [5] Wu K,Woo SM,Kwon TK.The histone lysine-specific demethylase 1 inhibitor,SP2509 exerts cytotoxic effects against renal cancer cells through downregulation of Bcl-2 and Mcl-1[J].Cancer Prev,2020,25(2):79-86. [6] Chen Y,Cao J,Zhang N,et al.Advances in differentiation therapy for osteosarcoma[J].Drug Discov Today,2020,25(3):497-504. [7] Makovec T.Cisplatin and beyond:molecular mechanisms of action and drug resistance development in cancer chemotherapy[J].Radiol Oncol,2019,53(2):148-158. [8] Phitjira Sanguanboonyaphong,Patcharee Komvilaisak,Kunanya Suwannaying,et al.Predictors of chemotherapy induced adverse events in pediatric osteosarcoma patients[J].Asian Pac Cancer Prev,2022,23(1):93-100. [9] Yang Li,Gaoxia Yang,Chengcan Yang,et al.Targeting autophagy-related epigenetic regulators for cancer drug discovery[J].Med Chem,2021,10(64):11798-11815. [10] Sheng W,LaFleur MW,Nguyen TH,et al.LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade[J].Cell,2018,174(3):549-563. [11] Xie Q,Tang T,Pang J,et al.LSD1 promotes bladder cancer progression by upregulating LEF1 and enhancing EMT[J].Front Oncol,2020,28(10):1234-1245. [12] Fu X,Zhang P,Yu B.Advances toward LSD1 inhibitors for cancer therapy[J].Future Med Chem,2017,9(11):1227-1242. [13] Piffoux M,Eriau E,Cassier PA.Autophagy as a therapeutic target in pancreatic cancer[J].Br Cancer,2021,124(2):333-344. [14] Wei Y,Han T,Wang R,et al.LSD1 negatively regulates autophagy through the mTOR signaling pathway in ovarian cancer cells[J].Oncol Rep,2018,40(1):425-433. [15] Chao A,Lin CY,Chao AN,et al.Lysine-specific demethylase 1 (LSD1) destabilizes p62 and inhibits autophagy in gynecologic malignancies[J].Oncotarget,2017,8(43):74434-74450.
2022, Vol. 28 
冀公网安备13080202000677号